Seite auswählen

MedImmune, an American biotechnology company arm of AstraZeneca since 2007, and WuXi AppTec, a leading research and development outsourcing comapny have established a joint venture in the Chinese market. The aim of the joint venture is the development and marketing of MEDI5117, a novel biologic for autoimmune and inflammatory diseases.

MedImmune will provide technical and development expertise, while WuXi AppTec brings local regulatory knowledge, alongside manufacturing, pre-clinical and clinical trial support. When undertaking clinical studies, Chinese government requires local manufacturing of medicines, that have yet to be approved in other markets.

[ilink url=“–/de/News/24246375″] Link zur Quelle (Adhoc-News)[/ilink]